T Cell Diversity in Tumor May Influence Ovarian Cancer Outcomes

Video

In this video Dr. Odunsi discusses a new study that found that higher T-cell diversity in ovarian cancer is associated with poor overall survival.

A new study has found that higher T-cell diversity in ovarian cancer is associated with poor overall survival. Researchers used deep T-cell receptor sequencing to evaluate the clonal composition of tumor-infiltrating lymphocytes in an attempt to identify new prognostic biomarkers in ovarian cancer.

The results of the study (abstract 5546) were presented by Kunle Odunsi, MD, PhD, of the Roswell Park Cancer Institute in Buffalo, New York, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3–7 in Chicago. Here Dr. Odunsi discusses the results of the study and highlights other interesting ASCO studies in gynecologic cancers.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Related Content